Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 11:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 13,471 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Ovarian Cancer
Interventions: carboplatin, doxorubicin hydrochloride; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 120 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Biliary Tract Cancer (BTC), Colorectal Cancer (CRC), Endometrial Cancer, Gastroesophageal Cancer (GC), Ovarian Cancer, Solid Tumors
Interventions: INCB001158, Oxaliplatin, Leucovorin, 5-Fluorouracil, Gemcitabine, Cisplatin, Paclitaxel; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 6
States / cities: Birmingham, Alabama • Mobile, Alabama • Sacramento, California + 3 more

Conditions: Diabetes Mellitus
Interventions: Telephone specialist consultation; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: Not listed
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2002
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, Exenatide, Dapagliflozin, Exenatide and Dapagliflozin; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 70 Years
Enrollment: 107 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Gestational Diabetes
Interventions: metformin, Glyburide; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 13 Years and older · Female only
Enrollment: 149 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2023
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Diabetes in Pregnancy, Gestational Diabetes, Texting Interventions
Interventions: Text Message Intervention; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Depressive Symptoms, Diabetes
Interventions: Vitamin D supplementation; Dietary Supplement
Lead sponsor: Loyola University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Hepatocellular Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Colorectal Cancer, Head and Neck Cancer, Differentiated Thyroid Cancer, Lower Esophageal Cancer
Interventions: cabozantinib, atezolizumab; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 914 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 57
States / cities: Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 45 more

Conditions: Prediabetic State
Interventions: Financial Incentives; Behavioral
Lead sponsor: Minnesota Department of Human Services; Government
Eligibility: 18 Years to 74 Years
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Diabetes
Interventions: lifestyle (exercise, diet, and family and community support); Behavioral
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2004
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Cancer, Non-small-cell Lung Cancer, Colorectal Cancer, Papillary Thyroid Cancer, Melanoma
Interventions: XL281, famotidine; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 6
States / cities: Scottsdale, Arizona • Tampa, Florida • Detroit, Michigan + 3 more

Conditions: Diabetes Mellitus Type 2
Interventions: GK Activator (2); Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 10
States / cities: Chandler, Arizona • Oviedo, Florida • Nampa, Idaho + 7 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Oral Insulin, Placebo; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 3 Years to 45 Years
Enrollment: 560 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 13
States / cities: San Francisco, California • Stanford, California • Aurora, Colorado + 10 more

Conditions: Fertility, Male Fertility, Sperm Count, Low, Sperm Quality
Interventions: EDC Education Intervention; Behavioral
Lead sponsor: Million Marker Wellness, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Berkeley, California

Conditions: Type 2 Diabetes Mellitus, Overweight, Obesity
Interventions: Low carbohydrate, ketogenic diet, Low glycemic index, reduced calorie diet; Behavioral
Lead sponsor: Robert C. Atkins Foundation; Other
Eligibility: 18 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Type 2 Diabetes
Interventions: Acceptance and Commitment Therapy, Abbott FreeStyle® Libre® 3, Generic Education; Behavioral · Device · Other
Lead sponsor: Sam Houston State University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Conroe, Texas

Conditions: Pancreatic Cancer
Interventions: S-1, gemcitabine hydrochloride; Drug
Lead sponsor: Andrew Ko; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: San Francisco, California • Baltimore, Maryland

Conditions: Diabetic Foot, Ulcer Foot
Interventions: Human split thickness skin allograft, Additional Outer Dressing Applicaiton, Offloading, Fibracol Wound Dressing; Other
Lead sponsor: Professional Education and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 5
States / cities: San Francisco, California • O'Fallon, Illinois • Youngstown, Ohio + 2 more

Conditions: Smoking Cessation
Interventions: Cognitive Behavioral Therapy for Smoking Cessation, Yoga, Health & Wellness; Behavioral
Lead sponsor: The Miriam Hospital; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
Interventions: ONC-392, Pembrolizumab, Docetaxel; Drug
Lead sponsor: OncoC4, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 733 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 33
States / cities: Springdale, Arkansas • Davis, California • Downey, California + 27 more

Conditions: Plantar Ulcer, Diabetes, Neuropathy Causing Loss of Protective Sensation
Interventions: TrueContour® Insole, Current standard of care insole; Device
Lead sponsor: DIApedia, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 11
States / cities: Phoenix, Arizona • Tucson, Arizona • Castro Valley, California + 8 more

Conditions: Metabolic Syndrome X, Overweight, Hypertension, Dyslipidemias, Prediabetic State
Interventions: Placebo Comparator: First Intervention (3 weeks), Active Comparator: Second Intervention (3 weeks), Active Comparator: Third Intervention (3 weeks), Active Comparator: Fourth Intervention (3 weeks); Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 60 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Diabetes Mellitus, Type 2, Cystic Fibrosis
Interventions: Oral Glucose Tolerance Test, High Glycemic Index Meal, Low Glycemic Index Meal, Test Soda, Fruit juice; Other
Lead sponsor: Emory University; Other
Eligibility: 1 Year and older
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Diabetes Type 2
Interventions: Vitamin E, Vitamin C; Dietary Supplement
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer

A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors

Computer-Assisted Access to Specialist Expertise

Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria

Metformin Compared to Glyburide in Gestational Diabetes

Sugar Text: A Randomized Controlled Trial of a Text Message Intervention for Women With Diabetes in Pregnancy

Vitamin D for Improving Metabolic Control and Depressive Symptoms

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Minnesota Medicaid Incentives to Prevent Chronic Disease

Family-Centered Diabetes Project

Study of XL281 in Adults With Solid Tumors

A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.

Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus

Sperm, Exposure and Endocrine Disruptors

Lifestyle Modification for Obesity-Related Type 2 Diabetes

ACT Intervention for Type 2 Diabetes Management for Rural and Underserved Community

Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer

Bioactive Split Thickness Skin Allograft Versus Standard of Care in the Treatment of Diabetic Foot Ulcers

Yoga for Men Attempting Smoking Cessation

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

The CareFUL Prevention Trial

Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)

Redox Imbalance and the Development of Cystic Fibrosis Diabetes

Famine From Feast: Linking Vitamin C, Red Blood Cell Fragility, and Diabetes